...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >FORMULATION DEVELOPMENT OF MICROSPONGE BASED DELAYED RELEASE DOSAGE FORM OF LANSOPRAZOLE
【24h】

FORMULATION DEVELOPMENT OF MICROSPONGE BASED DELAYED RELEASE DOSAGE FORM OF LANSOPRAZOLE

机译:基于微囊的兰索唑缓释剂量配方的研制

获取原文

摘要

The aim of study is to develop microsponge based delayed release dosage form, technique used to manufacture microsponge was quasi emulsion diffusion technique. Eudragit L 100 and Eudragit S 100 polymer is used to incorporate lansoprazole in microsponge. Lansoprazole is acid labile drug hence release of lansoprazole was delayed from acid environment. Microsponge contains porous polymeric microspheres, typically 100 – 250 μm in diameter. Compatibility of the drug with adjuncts was studied by DSC. Production yield, loading efficiency, particle size analysis, surface morphology and in-vitro release studies were carried out. Optimized microsponge blended with other diluents and filled in capsules. Blend containing lansoprazole Microsponge were evaluated for SeDeM parameters to check its flow. The microsponge formulation F2 showed delayed release of lansoprazole in buffer stage pH 6.8 bypassing the acidic stage. The result reveals that developed microsponge are cost effective and can be used as a delivery system for acid labile drug lansoprazole to avoid its degradation in acidic media of the stomach. SeDeM technique can be employed for successive prediction powder blend performance.
机译:研究的目的是开发基于微海绵的延迟释放剂型,用于制造微海绵的技术是准乳液扩散技术。 Eudragit L 100和Eudragit S 100聚合物用于在微海绵中掺入兰索拉唑。兰索拉唑是酸不稳定的药物,因此兰索拉唑的释放延迟了酸性环境。微海绵包含多孔聚合物微球,直径通常为100 – 250μm。 DSC研究了药物与助剂的相容性。进行了产量,装载效率,粒度分析,表面形态和体外释放研究。优化的微海绵与其他稀释剂混合并装入胶囊。评估包含兰索拉唑微海绵的掺合物的SeDeM参数,以检查其流量。小海绵制剂F2在缓冲阶段pH 6.8中绕过酸性阶段显示了兰索拉唑的延迟释放。结果表明,开发的微海绵具有成本效益,可以用作酸不稳定药物兰索拉唑的输送系统,避免其在胃的酸性介质中降解。 SeDeM技术可用于连续预测粉末混合性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号